Full-Time

Manager – GMP Supplier Quality Management

Posted on 8/18/2026

United Therapeutics Corporation

United Therapeutics Corporation

Biotech company develops PAH therapies

No salary listed

Research Triangle Park, Durham, NC, USA

In Person

Bachelor's, Master's, PharmD, PhD

Category
Biology & Biotech (1)
Required Skills
Microsoft Office
GMP
Quality Assurance (QA)
Risk Management

Get referred to United Therapeutics Corporation

See people who can refer or advise you

Requirements
  • A Bachelor's Degree with 8 or more years of quality assurance experience, or a Master's Degree with 6 or more years of quality assurance experience, or a PhD/PharmD with 2 or more years of quality assurance experience.
  • At least 5 years of vendor oversight experience.
  • At least 2 years of direct people management or leadership experience.
  • Strong technical knowledge and experience within pharmaceutical or GMP-regulated operations, with the ability to interpret technical, quality, regulatory, and manufacturing documentation and translate requirements into practical supplier oversight expectations.
  • Demonstrated knowledge of applicable regulatory and quality system requirements, including current Good Manufacturing Practice, 21 CFR Parts 210 and 211, FDA Quality Management System Regulation, ISO 13485, ISO 14971, the European Union Medical Device Regulation, and relevant International Council for Harmonisation guidance.
  • Experience with supplier qualification, risk management, quality agreements, audits, and performance monitoring.
  • Sound judgment in quality risk assessment, compliance decision-making, and issue escalation.
  • Experience supporting regulatory inspections, notified body audits, customer audits, or internal quality audits.
  • Excellent written and verbal communication skills, including the ability to prepare clear quality agreements, executive summaries, procedures, and inspection responses.
Responsibilities
  • Manage the Supplier Quality Management program in alignment with FDA pharmaceutical and combination product regulations, including FDA Quality Management System Regulation and 21 CFR Part 4 requirements.
  • Assist with risk-based supplier qualification, approval, requalification, and disqualification processes for suppliers, contract manufacturers, contract laboratories, distributors, service providers, and critical material vendors.
  • Perform GxP vendor-list risk assessments to help develop the annual vendor audit schedule based on vendor impact, material criticality, supplier performance, regulatory history, quality-system maturity, and business-continuity risk.
  • Negotiate, establish, maintain, and periodically review supplier technical or quality agreements defining quality, compliance, notification, change-control, and documentation responsibilities.
  • Develop vendor key performance indicators and scorecards; monitor vendor quality performance through metrics, scorecards, trend analysis, management-review inputs, and escalation processes.
  • Participate as a liaison in vendor quality events, including deviations, nonconformance investigations, out-of-specification events, and corrective and preventive action implementation.
  • Manage intake and cross-functional coordination of vendor change notifications, including identifying impacted sites and locations and evaluating potential effects on product quality, regulatory filings, validated processes, specifications, labeling, and supply continuity.
  • Participate in or initiate vendor quality issue escalation, including material holds, supplier corrective action requests, field-impact assessments, recall support, and regulatory-inspection support.
  • Identify supplier quality trends and drive continuous-improvement initiatives to reduce quality events, improve Right First Time performance, and strengthen supplier capabilities.
  • Ensure vendor-management records are maintained according to company procedures and retention requirements.
  • Author, revise, and maintain vendor quality procedures, work instructions, templates, and training materials.
Desired Qualifications
  • Certified Quality Auditor certification from the American Society for Quality or another certifying body.
  • Certified Quality Manager certification from the American Society for Quality or another certifying body.
  • Knowledge of Microsoft Office, DocuSign, and electronic quality-management systems.
  • Knowledge of artificial-intelligence applications in supplier quality management, including predictive analytics for quality control and automation of routine tasks.
  • Ability to lead cross-functional teams, influence without direct authority, and communicate effectively with internal stakeholders and external suppliers.
United Therapeutics Corporation

United Therapeutics Corporation

View

United Therapeutics develops therapies for life-threatening diseases, with a focus on pulmonary arterial hypertension and rare conditions. Its approved medicines, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, treat PAH and pediatric neuroblastoma and are delivered by injections, inhalations, or oral tablets. The company also pursues regenerative medicine and xenotransplantation through its Lung Biotechnology PBC and Revivicor units to create bioengineered organs for transplant. It differentiates itself by combining drug development with organ engineering and by operating as a Public Benefit Corporation that balances profits with social and environmental goals, aiming to extend lives and increase access to transplantable organs.

Company Size

N/A

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1996

Get referred to United Therapeutics Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approved LungFX on June 29, 2026, with services targeted for 2027.
  • Second-quarter 2026 net income rose to $333 million despite softer revenue.
  • United Therapeutics bought Thymmune for $140 million, expanding transplant-tolerance programs.

What critics are saying

  • Tyvaso net sales fell in Q2 2026 as Yutrepia launches intensified.
  • Liquidia and Boehringer lawsuits threaten Treprostinil revenues and sales execution through 2027.
  • Tyvaso concentration makes a bad PAH cycle or trial failure existential.

What makes United Therapeutics Corporation unique

  • LungFX approval makes United Therapeutics first in centralized EVLP.
  • Thymmune acquisition deepens its organ-tolerance and regenerative-medicine moat.
  • Cash-rich rare-disease franchise funds organ manufacturing and xenotransplantation bets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Holidays

Paid Vacation

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Conference Attendance Budget

Professional Development Budget

Professional Certification Support

Tuition Reimbursement

Stock Options

Company Equity

Employee Stock Purchase Plan

Relocation Assistance

Employee Referral Bonus

Performance Bonus

Profit Sharing

Sabbatical Leave

Hybrid Work Options

Remote Work Options

Flexible Work Hours

ParentAL Leave

Company News

Investor's Business Daily
Aug 12th, 2026
Liquidia drops 4% despite $170M Yutrepia sales beat, misses earnings by 2 cents

Liquidia shares fell more than 4% on Wednesday despite the company's lung disease drug Yutrepia beating second-quarter sales expectations. The treatment generated $170.4 million in sales, growing 31% and surpassing forecasts of $166.4 million. However, the company posted earnings of 74 cents per share, slightly missing expectations of 76 cents. Yutrepia, which launched in June 2025, competes with United Therapeutics' Tyvaso in treating high blood pressure in the lungs. Since launch, Liquidia has received approximately 5,900 new patient prescriptions, with more than 5,000 patients starting treatment. Over 1,100 physicians now prescribe the drug. Liquidia stock has gained 155% year-to-date and ranks second on the IBD 50 list of elite growth stocks.

Yahoo Finance
Aug 7th, 2026
United Therapeutics reports $333M net income and $7.27 EPS as ralinepag files for FDA approval

United Therapeutics reported second-quarter 2026 results showing sales of $783.3 million, a slight year-on-year decline, whilst net income rose to $333 million and diluted earnings per share increased to $7.27. The company continued share repurchases under its $1.50 billion buyback programme, retiring 5.84% of shares. The biotech firm also published positive phase 3 ADVANCE OUTCOMES data for investigational pulmonary arterial hypertension therapy ralinepag and filed with the FDA. The stronger earnings per share partly reflects the shrinking share count from buybacks. Analysts remain divided on the company's future, with some projecting only 1.2% annual revenue growth and $1.4 billion earnings by 2029, citing concerns about its concentrated portfolio of pulmonary drugs and regulatory uncertainties.

Yahoo Finance
Jul 23rd, 2026
United Therapeutics appoints ex-National Academy of Medicine president Victor Dzau to board

United Therapeutics Corporation has appointed Victor Dzau to its board of directors, effective 22 July 2026. Dr Dzau recently completed a 12-year term as president of the National Academy of Medicine and previously served as chancellor for health affairs at Duke University and president of the Duke University Health System. Dr Dzau is recognised globally as a physician-scientist whose research laid the foundation for ACE inhibitors. He pioneered gene therapy for vascular disease and currently studies cardiac regeneration. Martine Rothblatt, chairperson and chief executive officer of United Therapeutics, said Dr Dzau is uniquely capable of guiding the company in its mission of developing transplantable organs and organ alternatives for patients with end-stage organ failure.

Yahoo Finance
Jul 11th, 2026
United Therapeutics wins FDA approval for LungFX device amid questions over valuation

United Therapeutics is under scrutiny after the US FDA approved its LungFX device for centralised ex vivo lung perfusion. The stock has shown strong momentum, with a year-to-date return of 10.13% and a one-year total shareholder return of 85.12%, though short-term prices have eased slightly. The company closed at $547.06, against a narrative fair value of $665.23, suggesting an 18% undervaluation. The valuation gap depends on whether LungFX, Tyvaso, and the broader pulmonary and organ platforms can drive future earnings. United Therapeutics' pipeline includes studies in progressive fibrosis, next-generation delivery platforms, and organ manufacturing technologies. However, the company faces risks from potential trial setbacks and drug pricing reforms that could impact profitability and cash flows.

Yahoo Finance
Jul 8th, 2026
United Therapeutics acquires Thymmune for $140M to advance organ transplant innovation

United Therapeutics Corporation acquired Thymmune Therapeutics for $140 million in cash, with potential additional earn-out payments of up to $160 million tied to clinical and regulatory milestones through 2031. Thymmune develops regenerative thymic cell therapies using human-induced pluripotent stem cells. The acquisition expands United Therapeutics' organ transplantation capabilities. The company focuses on treating life-threatening diseases, including pulmonary arterial hypertension, whilst addressing the global organ shortage through xenotransplantation, 3D bioprinting, and ex vivo lung perfusion technologies. Separately, the FDA granted premarket approval for LungFX, which Leerink Partners described as a regulatory advancement supporting the company's long-term organ manufacturing strategy. Leerink maintains an Outperform rating on United Therapeutics shares.